Niemann-Pick disease (NPD) refers to a group of autosomal recessive lysosomal storage disorders characterized by the accumulation of cholesterol and sphingolipids in various tissues[1]. The disease results from deficiency of acid sphingomyelinase (ASM) in types A and B, or defects in the NPC1/NPC2 cholesterol transport proteins in type C. This leads to progressive multi-organ involvement including the liver, spleen, brain, and lungs[2].
The three main types of Niemann-Pick disease are:
The combined incidence of all Niemann-Pick types is approximately 1 in 100,000 to 1 in 150,000 births[3].
Types A and B Niemann-Pick disease are caused by mutations in the SMPD1 gene on chromosome 11p15.4, which encodes acid sphingomyelinase (ASM)[4]. This enzyme catalyzes the hydrolysis of sphingomyelin to ceramide and phosphorylcholine within lysosomes. Over 200 disease-causing mutations have been identified, including missense, nonsense, splice site, and deletion mutations.
The genotype largely determines the phenotype:
The p.L302P, p.R496L, and p.deltaR608 mutations are common in patients of European descent, while other mutations show population-specific frequencies[5].
Type C Niemann-Pick disease involves defects in intracellular cholesterol transport[6]. Two main genes are implicated:
The NPC1 protein contains a cysteine-rich domain that binds cholesterol and other sterols. Mutations disrupt the movement of cholesterol from late endosomes and lysosomes to the endoplasmic reticulum and plasma membrane.
The accumulation patterns differ between types[7]:
NPD-A/B: Accumulation of sphingomyelin and other lipids in:
NPD-C: Accumulation of cholesterol and glycolipids in:
The accumulation of these lipids triggers cellular dysfunction, inflammation, and ultimately cell death.
NPD type A presents in early infancy with severe neurological involvement[8]:
The characteristic "cherry-red spot" is seen on ophthalmologic examination, resulting from accumulation of lipid in retinal ganglion cells that makes the macula appear red against the pale, lipid-laden surrounding retina.
NPD type B presents in childhood but has a variable course[9]:
Unlike type A, type B patients do not develop primary neurological deterioration, though some may show subtle neurocognitive findings.
Type C presents with variable combinations of visceral and neurological symptoms[10]:
Neurological manifestations include:
Visceral manifestations include:
The age of neurological onset is highly variable and determines the rate of progression.
The hallmark of Niemann-Pick disease is the accumulation of lipid-engorged macrophages called foam cells[11]. These cells form due to the inability to catabolize sphingomyelin (types A/B) or cholesterol (type C).
Foam cells accumulate in:
These cells are not merely storage containers but actively secrete inflammatory mediators, contributing to tissue damage and disease progression.
Sphingomyelin accumulation leads to dysregulation of bioactive sphingolipid metabolites[12]:
The balance between these metabolites determines cell survival versus death, with shifts toward pro-apoptotic signaling in Niemann-Pick disease.
The neurological manifestations of Niemann-Pick disease result from multiple mechanisms[13]:
In types A/B:
In type C:
The pattern of neurodegeneration varies between types but ultimately leads to severe neurological impairment.
In type C disease, the primary defect is in intracellular cholesterol transport[14]:
This cholesterol trafficking defect is also relevant to other neurodegenerative diseases, making NPD-C a valuable disease model.
Research has identified connections between Niemann-Pick disease and Alzheimer's disease[15]:
These connections suggest that understanding NPD may provide insights into AD pathogenesis.
NPD-C shares features with other neurodegenerative conditions[16]:
ERT for NPD types A/B is under development[17]:
Oral substrate reduction therapy options include[18]:
These therapies may stabilize disease progression but do not reverse existing neurological damage.
HSCT has been attempted in NPD type B[19]:
Several innovative therapies are in development[20]:
Supportive care remains essential[21]:
The Niemann-Pick disease pathway intersects with several neurodegenerative disease mechanisms:
Niemann-Pick disease represents a group of lysosomal storage disorders with significant overlap to broader neurodegenerative processes. Types A and B result from acid sphingomyelinase deficiency, while type C involves defective cholesterol transport. The disease mechanisms involving sphingolipid and cholesterol accumulation provide insights into neurodegenerative conditions including Alzheimer's disease. Treatment options remain limited, but emerging therapies including gene therapy and small molecule correctors offer hope for future interventions.
Wasserstein, M. P., & Schuchman, E. H. Acid sphingomyelinase deficiency. GeneReviews. 2006. ↩︎
Schuchman, E. H., & Desnick, R. J. Niemann-Pick disease types A and B: Acid sphingomyelinase deficiencies. The Online Metabolic and Molecular Bases of Inherited Disease. 2017. ↩︎
Jiang, X., et al. Niemann-Pick disease type C: History, mechanisms, and therapeutic approaches. Frontiers in Neuroscience. 2019. ↩︎
Simonaro, C. M., et al. Mechanism of cholesterol accumulation in the brains of mice and humans with Niemann-Pick type C disease. Human Molecular Genetics. 2005. ↩︎
Peng, Q., et al. SMPD1 mutations in Chinese patients with Niemann-Pick disease type A. Molecular Genetics and Metabolism. 2019. ↩︎
Vance, J. E., & Karten, B. Niemann-Pick type C disease and mobilization of cholesterol by HDL. Journal of Lipid Research. 2014. ↩︎
McGovern, M. M., et al. Niemann-Pick disease type C: Genetic landscape and disease mechanisms. Current Opinion in Genetic Development. 2017. ↩︎
Vollbach, H., et al. Clinical presentation and mutation spectrum in 36 patients with Niemann-Pick type C. Neuropediatrics. 2005. ↩︎
Simonaro, C. M., et al. Joint and bone disease in mice and humans with acid sphingomyelinase deficiency (ASMD). Pediatric Research. 2002. ↩︎
Sevin, C., et al. Niemann-Pick type C disease: Childhood presentation and therapeutic options. Revue Neurologique. 2006. ↩︎
Liscum, L., & Faust, J. R. The intracellular transport of cholesterol and beta-sitosterol in Niemann-Pick type C disease. Journal of Biological Chemistry. 1987. ↩︎
Jenkins, R. W., et al. Sphingolipid metabolites in inflammatory disease. Journal of Biological Chemistry. 2011. ↩︎
Zhang, H., et al. Niemann-Pick disease type C: Lysosomal cholesterol and beyond. Molecular Genetics and Metabolism. 2018. ↩︎
Liao, J., et al. Cholesterol trafficking in health and disease. Trends in Molecular Medicine. 2017. ↩︎
Jiang, Y., et al. Altered sphingolipid metabolism in Alzheimer's disease. Molecular Neurobiology. 2020. ↩︎
Vanier, M. T. Niemann-Pick disease type C. Orphanet Journal of Rare Diseases. 2010. ↩︎
Thurberg, B. L., et al. Enzyme replacement therapy for type A Niemann-Pick disease. Molecular Genetics and Metabolism. 2005. ↩︎
Patterson, M. C., et al. Miglustat in Niemann-Pick type C disease. Journal of Inherited Metabolic Disease. 2013. ↩︎
Stein, J., et al. Hematopoietic stem cell transplantation for Niemann-Pick disease. Molecular Genetics and Metabolism. 2012. ↩︎
Song, Y. L., et al. Gene therapy for Niemann-Pick disease type C. Human Gene Therapy. 2021. ↩︎
Patterson, M. C., et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C. Molecular Genetics and Metabolism. 2017. ↩︎